Sotrovimab Monoclonal Antibody Remains in Short-Supply

The U.S. HHS Assistant Secretary for Preparedness and Response (ASPR) confirmed in an update issued on January 17, 2022, it would distribute 52,064​ doses of sotrovimab, an innovative anti-SARS-CoV-2 monoclonal antibody (mAbs) treatment.

Since October 2021, about 437,00 sotrovimab doses have been shipped to U.S. states, territories, and agencies.

To resolve the current mAbs supply constraints, GSK and Vir Biotechnology, Inc. announced on January 11 that the U.S. Government would purchase an additional 600,000 doses of sotrovimab to be delivered throughout the first quarter of 2022.

Sotrovimab is not available for retail purchase as of January 18.

GSK recently confirmed the total number of Sotrovimab (Xevudy) doses secured committed through binding agreements is approximately 1.7 million globally.

And from an authorization perspective, Sotrovimab has been invited for WHO Prequalification, which increases access in lower-income countries. 

Find facilities in the USA that administer monoclonal antibodies using the HHS Therapeutics Distribution Locator to find potential mAbs supplies.

In addition, sotrovimab has demonstrated effectiveness against all tested variants of concern and interest defined by the World Health Organization. 

As of January 18, the U.S. NIH OpenData Portal reported Sotrovimab's effectiveness against the Omicron virus variant. 

Note: On May 26, 2021, GlaxoSmithKline LLC received Emergency Use Authorization from the U.S. Food and Drug Administration for sotrovimab. VIR Bio and GSK received funding support through the U.S. Operation Warp Speed.